What is Zacks Research’s Estimate for Perrigo Q1 Earnings?

Perrigo Company plc (NYSE:PRGO) – Stock analysts at Zacks Research reduced their Q1 2026 earnings per share estimates for shares of Perrigo in a research report issued on Thursday, March 19th. Zacks Research analyst Team now forecasts that the company will earn $0.57 per share for the quarter, down from their prior estimate of $0.78. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Perrigo’s current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Perrigo’s Q2 2026 earnings at $0.45 EPS, Q3 2026 earnings at $0.55 EPS, Q4 2026 earnings at $0.61 EPS, FY2026 earnings at $2.18 EPS, Q1 2027 earnings at $0.69 EPS, Q3 2027 earnings at $0.63 EPS, Q4 2027 earnings at $0.66 EPS and FY2027 earnings at $2.53 EPS.

Perrigo (NYSE:PRGO) last issued its earnings results on Thursday, February 26th. The company reported $0.77 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.80 by ($0.03). The company had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.09 billion. Perrigo had a positive return on equity of 9.41% and a negative net margin of 33.51%.The business’s revenue was down 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.93 earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS.

A number of other analysts have also commented on the stock. Jefferies Financial Group reaffirmed a “hold” rating on shares of Perrigo in a research note on Thursday, February 26th. Argus raised shares of Perrigo to a “hold” rating in a research report on Wednesday, January 14th. Canaccord Genuity Group cut their price target on shares of Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Weiss Ratings restated a “sell (d+)” rating on shares of Perrigo in a research report on Monday, December 22nd. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Perrigo from $20.00 to $18.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Perrigo currently has a consensus rating of “Reduce” and a consensus price target of $19.33.

Perrigo Trading Up 0.8%

NYSE:PRGO opened at $9.65 on Monday. The stock has a fifty day simple moving average of $13.07 and a 200 day simple moving average of $15.82. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of -0.94, a price-to-earnings-growth ratio of 1.13 and a beta of 0.41. Perrigo has a 1-year low of $9.23 and a 1-year high of $28.43. The company has a quick ratio of 1.63, a current ratio of 2.76 and a debt-to-equity ratio of 1.23.

Institutional Investors Weigh In On Perrigo

Institutional investors have recently made changes to their positions in the company. Amundi increased its holdings in Perrigo by 11.7% in the first quarter. Amundi now owns 5,292 shares of the company’s stock worth $148,000 after buying an additional 556 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Perrigo by 126.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock valued at $32,520,000 after acquiring an additional 647,982 shares during the last quarter. United Services Automobile Association bought a new stake in Perrigo in the first quarter worth approximately $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Perrigo by 6.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,112 shares of the company’s stock worth $14,388,000 after purchasing an additional 32,151 shares during the last quarter. Finally, Geneos Wealth Management Inc. increased its stake in shares of Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after purchasing an additional 786 shares during the last quarter. 95.91% of the stock is currently owned by institutional investors and hedge funds.

Perrigo Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 24th. Shareholders of record on Monday, March 2nd were given a $0.29 dividend. This represents a $1.16 annualized dividend and a yield of 12.0%. The ex-dividend date of this dividend was Monday, March 2nd. Perrigo’s dividend payout ratio is presently -11.28%.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.